ZVSA (ZyVersa Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


ZVSA ZyVersa Therapeutics Inc ZVSA
30 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is ZyVersa Therapeutics OCF Margin %?

ZyVersa Therapeutics ZVSA +5.65% 30 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ZVSA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, ZyVersa Therapeutics ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. ZyVersa Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-0.80 Mil. ZyVersa Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, ZyVersa Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, ZyVersa Therapeutics's current OCF Yield % is -273.58%.

The historical rank and industry rank for ZyVersa Therapeutics's OCF Margin % or its related term are showing as below:


ZVSA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

ZyVersa Therapeutics OCF Margin % Related Terms

ZyVersa Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for ZyVersa Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZyVersa Therapeutics OCF Margin % Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ZyVersa Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZVSA
30GF Score
ZyVersa Therapeutics Inc ZVSA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZyVersa Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

ZyVersa Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.114/0
= %

ZyVersa Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.799/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
ZyVersa Therapeutics (ZVSA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ZyVersa Therapeutics and its competitors. According to the industry distribution chart, ZyVersa Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is ZyVersa Therapeutics' OCF Margin % too high?
ZyVersa Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, ZyVersa Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ZyVersa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ZyVersa Therapeutics' OCF Margin % compare to CLSDQ and ADAPY?
According to the Biotechnology industry distribution chart, ZyVersa Therapeutics ranks #999999 out of 960 companies for OCF Margin %. This places ZyVersa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ZyVersa Therapeutics and its competitors. ZyVersa Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZyVersa Therapeutics stock overvalued right now?
ZyVersa Therapeutics (ZVSA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. ZyVersa Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For ZyVersa Therapeutics (ZVSA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZyVersa Therapeutics Business Description

Address 2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
30GF Score

Get the complete analysis for ZVSA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price